



13794 NW 4th Street
Suite 212
Sunrise, FL 33325
Telephone 954-835-1500
Email: rmadaris@bioheartinc.com

For Immediate Release

Bioheart Appoints Kristin Comella to Board of Directors

Sunrise, FL – March 14th, 2013 - Bioheart Inc. (BHRT.QB) is pleased to announce the appointment of Kristin C. Comella to the Board of Directors. Ms. Comella has been a member of senior management since 2004 and will continue to serve as the Chief Science Officer for the Company.

Dr. William P. Murphy Jr. Chairman of the Board commented, “Over the years I have worked alongside some of the brightest scientific minds; Kristin is no exception. Her leadership and collective scientific advancements have made Bioheart a leader in the field of regenerative medicine. Her addition to the Board of Bioheart will prove invaluable.”

Ms. Comella replaces Richard T. Spencer III who has resigned from the Company’s Board of Directors after over a decade of service.

Mr. Spencer said, "I leave this board in great and capable hands. Dr Murphy has traveled this road more than once, so he has been inspiring and credible as our Chairman, and our entire team has been staunchly determined to succeed in our belief that our

technology and medical insights will prevail and that Bioheart will make landmark contributions within the annals of medicine."

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.